Slide 12010 Guidelines Case Study #1 Mrs. DT 2010 Guidelines Slide 2 Case Presentation Age 59: nine years post-menopause with treated osteoporosis Has always enjoyed excellent…

Slide 1Using genetic markers in clinical practice David Thomas Advisor: Merck Clinical trial: Gilead and Merck Slide 2 Using genetic markers in clinical practice IL28b test…

Slide 1Boceprevir Combined with Peginterferon alfa-2b/Ribavirin for Treatment-Naïve Patients with HCV Genotype 1 SPRINT-2 Final Results Mark S. Sulkowski, Fred Poordad,…

Slide 1HIV and Aging: a Time for a New Paradigm Amy C. Justice, MD, MSCE, PhD Professor, Yale University Section Chief, General Internal Medicine VA Connecticut Healthcare…

Slide 1Hepatitis web study Hepatitis web study Sofosbuvir + (Ledipasvir or GS-9669) +/- Ribavirin in GT-1 ELECTRON Trial (Arms 12-17 & 22) Phase 2 Treatment Naïve and…

Slide 1Practitioner’s Edge is a registered service mark of Integrity Continuing Education, Inc. © 2014 Integrity Continuing Education, Inc. Sponsored by Integrity Continuing…

1. Jorge Velasco ZamoraRheumatology SpecialistInternal Medicine Specialist Certified Physician Investigator (Academy ofPharmaceutical Physicians and Investigator)Master in…

Slide 1 Highlights from CROI 18th Conference on Retroviruses and Opportunistic Infections Boston, MA February 28 to March 3, 2011 Iván Meléndez-Rivera, MD Assistant Professor…

Slide 1 REYATAZ  Safety & Tolerability Issues for HIV ‑ Infected Patients Requiring Protease Inhibitor Therapy Slide 2 Disclaimer This slide set has been developed…

Slide 1 CONFIDENTIAL Investor Call December 9, 2010 Claire L. Kruger, Ph.D., Chief Executive Officer Robert A. Lodder, Ph.D., President Slide 2 What is D-tagatose? D-Tagatose…